Reverse hybrid therapy achieves a similar eradication rate as standard hybrid therapy for Helicobacter pylori infection.
Adult
Aged
Amoxicillin
/ administration & dosage
Clarithromycin
/ administration & dosage
Drug Therapy, Combination
Female
Helicobacter Infections
/ drug therapy
Helicobacter pylori
/ drug effects
Humans
Male
Medication Adherence
Metronidazole
/ administration & dosage
Middle Aged
Proton Pump Inhibitors
/ administration & dosage
Retrospective Studies
Journal
Journal of the Chinese Medical Association : JCMA
ISSN: 1728-7731
Titre abrégé: J Chin Med Assoc
Pays: Netherlands
ID NLM: 101174817
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
pubmed:
15
1
2020
medline:
31
8
2021
entrez:
15
1
2020
Statut:
ppublish
Résumé
Reverse hybrid therapy is a simplified hybrid treatment for Helicobacter pylori infection. It achieves a higher eradication rate than standard triple therapy. This study aimed to compare the efficacies of reverse hybrid and hybrid therapies in the treatment of H. pylori infection. From September 2008 to September 2017, 490 H. pylori-infected patients who received 14 days of reverse hybrid therapy (proton pump inhibitor plus amoxicillin for 14 days and clarithromycin plus metronidazole for the initial 7 days; n = 252) or hybrid therapy (proton pump inhibitor plus amoxicillin for 14 days and clarithromycin plus metronidazole for the final 7 days; n = 238) were included in this retrospective cohort study. Helicobacter pylori status was examined 6-8 weeks after therapy. The eradication rates of the reverse hybrid and hybrid therapies by modified intention-to-treat analysis were comparable (96.4% vs 96.6%; p = 0.899). There were no differences in the efficacy of eradication between therapies for clarithromycin-resistant strains (87.0% vs 90.0%) or metronidazole-resistant strains (97.7% vs 100.0%). In addition, there were comparable frequencies of adverse events for both treatments (18.7% vs 13.0%) and treatment adherence (94.4% vs 97.1%). Reverse hybrid therapy can achieve a similar eradication rate to hybrid therapy for H. pylori infection.
Sections du résumé
BACKGROUND
BACKGROUND
Reverse hybrid therapy is a simplified hybrid treatment for Helicobacter pylori infection. It achieves a higher eradication rate than standard triple therapy. This study aimed to compare the efficacies of reverse hybrid and hybrid therapies in the treatment of H. pylori infection.
METHODS
METHODS
From September 2008 to September 2017, 490 H. pylori-infected patients who received 14 days of reverse hybrid therapy (proton pump inhibitor plus amoxicillin for 14 days and clarithromycin plus metronidazole for the initial 7 days; n = 252) or hybrid therapy (proton pump inhibitor plus amoxicillin for 14 days and clarithromycin plus metronidazole for the final 7 days; n = 238) were included in this retrospective cohort study. Helicobacter pylori status was examined 6-8 weeks after therapy.
RESULTS
RESULTS
The eradication rates of the reverse hybrid and hybrid therapies by modified intention-to-treat analysis were comparable (96.4% vs 96.6%; p = 0.899). There were no differences in the efficacy of eradication between therapies for clarithromycin-resistant strains (87.0% vs 90.0%) or metronidazole-resistant strains (97.7% vs 100.0%). In addition, there were comparable frequencies of adverse events for both treatments (18.7% vs 13.0%) and treatment adherence (94.4% vs 97.1%).
CONCLUSION
CONCLUSIONS
Reverse hybrid therapy can achieve a similar eradication rate to hybrid therapy for H. pylori infection.
Identifiants
pubmed: 31934941
doi: 10.1097/JCMA.0000000000000256
pii: 02118582-202003000-00006
doi:
Substances chimiques
Proton Pump Inhibitors
0
Metronidazole
140QMO216E
Amoxicillin
804826J2HU
Clarithromycin
H1250JIK0A
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
233-237Références
Hsu PI, Lai KH, Hsu PN, Lo GH, Yu HC, Chen WC, et al. Helicobacter pylori infection and the risk of gastric malignancy.Am J Gastroenterol2007102725–30
Suerbaum S, Michetti P. Helicobacter pylori infection.N Engl J Med20023471175–86
Gumurdulu Y, Serin E, Ozer B, Kayaselcuk F, Ozsahin K, Cosar AM, et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.World J Gastroenterol200410668–71
De Francesco V, Margiotta M, Zullo A, Hassan C, Giorgio F, Burattini O, et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy.J Antimicrob Chemother200759783–5
Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections.Nat Clin Pract Gastroenterol Hepatol20085321–31
Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al.; European Helicobacter and Microbiota Study Group and Consensus panelManagement of Helicobacter pylori infection-the maastricht V/florence consensus report.Gut2017666–30
Huang CC, Tsai KW, Tsai TJ, Hsu PI. Update on the first-line treatment for Helicobacter pylori infection – a continuing challenge from an old enemy.Biomark Res2017523
Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.Helicobacter201116139–45
Oh DH, Lee DH, Kang KK, Park YS, Shin CM, Kim N, et al. Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy.J Gastroenterol Hepatol2014291171–6
De Francesco V, Hassan C, Ridola L, Giorgio F, Ierardi E, Zullo A. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study.J Med Microbiol201463Pt 5748–52
Sardarian H, Fakheri H, Hosseini V, Taghvaei T, Maleki I, Mokhtare M. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial.Helicobacter201318129–34
Molina-Infante J, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance.Gastroenterology2013145121–8.e121
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection.Am J Gastroenterol2017112212–39
Mahachai V, Vilaichone RK, Pittayanon R, Rojborwonwitaya J, Leelakusolvong S, Maneerattanaporn M, et al. Helicobacter pylori management in ASEAN: the Bangkok consensus report.J Gastroenterol Hepatol20183337–56
Sheu BS, Wu MS, Chiu CT, Lo JC, Wu DC, Liou JM, et al. Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale.Helicobacter201722
Hsu PI, Kao SS, Wu DC, Chen WC, Peng NJ, Yu HC, et al.; Taiwan Acid-Related Disease Study GroupA randomized controlled study comparing reverse hybrid therapy and standard triple therapy for Helicobacter pylori infection.Medicine (Baltimore)201594e2104
Hsu PI, Tsay FW, Graham DY, Tsai TJ, Tsai KW, Kao JY, et al.; Taiwan Acid-related Disease (TARD) Study GroupEquivalent efficacies of reverse hybrid and bismuth quadruple therapies in eradication of Helicobacter pylori infection in a randomized controlled trial.Clin Gastroenterol Hepatol2018161427–33
Wu DC, Hsu PI, Tseng HH, Tsay FW, Lai KH, Kuo CH, et al. Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies.Medicine (Baltimore)201190180–5
Peng NJ, Lai KH, Liu RS, Lee SC, Tsay DG, Lo CC, et al. Endoscopic 13C-urea breath test for the diagnosis of Helicobacter pylori infection.Dig Liver Dis20033573–7
Hsu PI, Wu DC, Wu JY, Graham DY. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days?Helicobacter201116146–52
Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection.Clin Gastroenterol Hepatol2010836–41.e1
Tsay FW, Wu DC, Kao SS, Tsai TJ, Lai KH, Cheng JS, et al. Reverse sequential therapy achieves a similar eradication rate as standard sequential therapy for Helicobacter pylori eradication: a randomized controlled trial.Helicobacter20152071–7
Oh B, Kim BS, Kim JW, Kim JS, Koh SJ, Kim BG, et al. The effect of probiotics on gut microbiota during the Helicobacter pylori eradication: randomized controlled trial.Helicobacter201621165–74
Yap TW, Gan HM, Lee YP, Leow AH, Azmi AN, Francois F, et al. Helicobacter pylori eradication causes perturbation of the human gut microbiome in young adults.PLoS One201611e0151893
Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy.Aliment Pharmacol Ther200725155–68
Wang ZJ, Chen XF, Zhang ZX, Li YC, Deng J, Tu J, et al. Effects of anti-Helicobacter pylori concomitant therapy and probiotic supplementation on the throat and gut microbiota in humans.Microb Pathog2017109156–61
Hsu PI, Pan CY, Kao JY, Tsay FW, Peng NJ, Kao SS, et al.; Taiwan Acid-related Disease (TARD) Study GroupHelicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of proteobacteria and decreased relative abundances of bacteroidetes and actinobacteria.Helicobacter201823e12498
Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. Triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability.Am J Gastroenterol201010565–73
Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence.Clin Gastroenterol Hepatol201412177–86.e173Discussion e112–73
Hsu PI, Wu DC, Chen WC, Tseng HH, Yu HC, Wang HM, et al. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection.Antimicrob Agents Chemother2014585936–42
Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, et al.; Taiwan Helicobacter ConsortiumSequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.Lancet2013381205–13
Tsay FW, Wu DC, Yu HC, Kao SS, Lin KH, Cheng JS, et al. A randomized controlled trial shows that both 14-Day hybrid and bismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with moderate antibiotic resistance.Antimicrob Agents Chemother201761e00140–17
Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.Drug Metab Pharmacokinet200520153–67
Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.Am J Gastroenterol20061011467–75
Hsu PI, Lai KH, Lin CK, Chen WC, Yu HC, Cheng JS, et al. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication.Am J Gastroenterol20051002387–92